Patent-ly problematic
India’s IP regime is being hauled up for not being industry friendly enough by the biotechnology Industry Association (BIA). Business Standard reports – The association raised the following concerns: 1. Indian laws lack clarity with regard to the patentability of biomolecules like nucleic acids.2. The provisions dealing with disallowing patents for known products which do not result in significant enhancement of efficacy.3. India’s capacity to include data protection clauses for medicines.4. The “onerous” obligations relating to the disclosure of source […]
Patent-ly problematic Read More »